CEO of Milford life sciences company steps down
Photo | Courtesy of Rentschler Biopharma
Frank Mathias
Frank Mathias will step down as the CEO of Rentschler Biopharma SE, which has its American base of operations in Milford, and will join Oxford Biomedica plc in England in March.
Mathias served as Rentschler Biopharma SE’s CEO for seven years, according to a Monday press release from the German-based Rentschler.
Mathias will replace Oxford Biomedica’s interim CEO Roch Doliveux, who will go back to his role as non-executive chair. Oxford Biomedica opened Oxford Biomedica Solutions in Bedford, Massachusetts, in early 2022. The company has partnerships with major pharmaceutical companies Bristol Myers Squibb, Novartis AG, and AstraZeneca plc.
Mathias will join the German life sciences company’s supervisory board in March, at the end of fiscal year, according to Rentschler.
After joining Rentschler Biopharma’s supervisory board in 2013, Mathias became its CEO and chairman of the executive board in 2016. Under his leadership, the company acquired the Milford manufacturing site in 2019. In 2021, it announced it began construction on additional manufacturing space in Milford with the building of an additional 22,000 square feet of manufacturing space, which will have four new single-use bioreactors, which use disposable bags and reduce the cost of sterilization in the process of culturing cells.
Rentschler Biopharma also established a cell and gene therapy site in Stevenage, England. The company employs more than 1,200 people.
WBJ Web Partners
Most Recent
Most Recent
0 Comments